Company Overview
GenAssist develops biomaterials that regenerate muscle tissue. Orthopedic trauma surgeons, reconstructive plastic surgeons, urogynecologists, and Physical Medicine & Rehabilitation (PM&R) physicians can use GenAssist’s patented flagship technology, MyoMatrix, to heal muscle wounds from high-impact trauma, disease, and other injuries. GenAssist won a $295K Phase I SBIR grant from the National Science Foundation and is now testing MyoMatrix in a large animal model of muscle trauma.
Team
Gabe
Haas
CTO
Joe Beggs
CEO
Dr. Koyal Garg
Principal Scientist
Gabe co-invented MyoMatrix and spearheads its development. As the CTO, he leads R&D for MyoMatrix, oversees regulatory affairs, and manages GenAssist’s finances. He acts as the principal investigator for our $295k NSF SBIR award and is a listed author on 10 publications, two patents, and a textbook chapter.
Joe leads fundraising and partnerships, raising over $500k for GenAssist. Across his ventures, he has secured over $1M, including investments from Baxter, Endeavor Health, and Hologic. With 3 publications, 2 patents, a clinical trial, and launch of a medical device, Joe confidently leads GenAssist towards commercial success.
Dr. Garg is an Associate Professor of Biomedical Engineering at Saint Louis University and runs the Musculoskeletal Tissue Engineering Laboratory, where MyoMatrix was invented. She provides scientific guidance, collaborates on grant applications, and conducts research on early-stage GenAssist products.
Headquatered at BioSTL
The BioSTL Building at 4340 Duncan Avenue includes 80,000 square feet of rentable, state-of-the-art office, lab and modular spaces to help support St. Louis startups in need of affordable, functional space in which to grow and thrive.